mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-17. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
=== Extraterrestrial amino acids === Amino acids in carbonaceous chondrites have important implications for theories describing the delivery of organic compounds to the early Earth and the subsequent development of life. Shortly after its fall and recovery in Australia in 1969, the Murchison meteorite was found to host five protein amino acids (glycine, alanine, valine, proline, and glutamic acid) in addition to 12 non-proteinogenic amino acids including α-aminoisobutyric acid and isovaline, which are rare on Earth. Since then, the number of characterised amino acids in the Murchison meteorite has risen to 96, including 12 of the 20 common biological amino acids, along with hundreds more that have been detected, but remain uncharacterised. While the abundance of amino acids present in terrestrial soils presents a potential source of contamination, most of the amino acids characterised in Murchison are terrestrially rare or absent. Amino acids may be structurally chiral, meaning that they have two possible non-superimposable mirror image structures, termed enantiomers. Conventionally, these are referred to as left-handed (L) and right-handed (D) by analogy with glyceraldehyde. Living beings use L-amino acids, although there is no apparent reason why one enantiomer is favoured over the other as they behave equivalently in biological systems.
=== Leadership rival === Although (or perhaps because) many of Heseltine's policy positions were not far removed from those of Labour, which was shifting to the right under Kinnock, he kept up his Conservative credentials at this time. In alliance with Norman Tebbit he persuaded ministers to abolish the Inner London Education Authority. He also supported the government's planned market-led reforms to the NHS and water privatisation in 1989. He also spoke out frequently on defence matters, supported the government's ban on Spycatcher, the new Official Secrets Act 1989 and called for an independent Bank of England, although perhaps as a stepping stone to the setting up of a European Central Bank. One of the reasons which Thatcher gave to close confidants for not retiring on her tenth anniversary as Prime Minister (May 1989) was worry that Heseltine would defeat Geoffrey Howe in any subsequent leadership election. Opinion polls showed that Heseltine would boost Conservative support by 13 percentage points – enough to overtake Labour. Sir Anthony Meyer wanted to see Heseltine as leader and only went ahead with his December 1989 leadership challenge to Thatcher on being assured by Keith Hampson that it would not damage Heseltine's chances; in the event Heseltine apparently walked up and down the corridor outside the voting booth making clear that he was abstaining.
== Synthesis == The traditional route to dithiothreitol (and its isomer dithioerythritol) is sulfidation of the extremely lachrymatory 1,4-Dibromobut-2-ene. Modern industrial syntheses instead use related epoxides and hydrogen sulfide.
Sources: en.wikipedia.org
He also holds patents for several processes he has developed. Ajayaghosh is associated with several science journals around the world. He is an associate editor of Physical Chemistry Chemical Physics (PCCP), published by the Royal Society of Chemistry and a senior editor of the Bulletin of the Chemical Society of Japan. He is a former member of the advisory board of RSC Advances and sits in the editorial board of Chemistry: An Asian Journal. He has also guided several master's and doctoral scholars in their studies and has been involved in programs for the popularization of science and science awareness campaigns.
Panic disorder with or without agoraphobia. Body dysmorphic disorder Repetitive self-injurious/self-harming behaviours in those with intellectual disability specifically. The subtype of systemised paranoia characterised by somatic phenomena. Compulsive nail-biting (onychophagia). Cataplexy associated with narcolepsy. This is a TGA and MHRA-labeled indication for clomipramine. Self-bloodletting Premature ejaculation, where it may be more effective than paroxetine Depersonalization-derealization disorder Chronic pain with or without organic disease, particularly headache of the tension type. Developmental stuttering Sleep paralysis, with or without narcolepsy Enuresis (involuntary urinating in sleep) in children. The effect may not be sustained following treatment, and alarm therapy may be more effective in both the short-term and the long-term. Combining a tricyclic (such as clomipramine) with anticholinergic medication may be more effective for treating enuresis than the tricyclic alone. Trichotillomania In combination with lithium and tryptophan for severe, particularly treatment-resistant depression. This combination, in a similar vein, has also been used for clomipramine-resistant obsessive-compulsive disorder. When electro-convulsive therapy is performed alongside this treatment-regime (as may be the case in severe depression and accompanied with thyroxine,) however, great care must be taken with lithium. The overall risk of seizures may have to be weighted against the refractory severity of the current illness and necessity of the amalgamation of treatment(s).
== Side effects == As a tetracycline derivative, tigecycline exhibits similar side effects to the class of antibiotics. Gastrointestinal (GI) symptoms are the most common reported side effect. Common side effects of tigecycline include nausea and vomiting. Nausea (26%) and vomiting (18%) tend to be mild or moderate and usually occur during the first two days of therapy. Rare adverse effects (<2%) include: swelling, pain, and irritation at injection site, anorexia, jaundice, hepatic dysfunction, pruritus, acute pancreatitis, and increased prothrombin time.
== Methods for determining catalase activity == In 1870, Schoenn discovered a formation of yellow color from the interaction of hydrogen peroxide with molybdate; then, from the middle of the 20th century, this reaction began to be used for colorimetric determination of unreacted hydrogen peroxide in the catalase activity assay. The reaction became widely used after publications by Korolyuk et al. (1988) and Goth (1991). The first paper describes serum catalase assay with no buffer in the reaction medium; the latter describes the procedure based on phosphate buffer as a reaction medium. Since phosphate ion reacts with ammonium molybdate, the use of MOPS buffer as a reaction medium is more appropriate. Direct UV measurement of the decrease in the concentration of hydrogen peroxide is also widely used after the publications by Beers & Sizer and Aebi.
Sources: en.wikipedia.org
The urine test may be a chromatographic immunoassay or any of several other test formats, home-, physician's office-, or laboratory-based. Published detection thresholds range from 20 to 100 mIU/mL, depending on the brand of test. Early in pregnancy, more accurate results may be obtained by using the first urine of the morning (when urine is most concentrated). When the urine is dilute (specific gravity less than 1.015), the hCG concentration may not be representative of the blood concentration, and the test may be falsely negative. The serum test, using 2-4 mL of venous blood, is typically a chemiluminescent or fluorimetric immunoassay that can detect βhCG levels as low as 5 mIU/mL and allows quantification of the βhCG concentration.
Aquasomes are self-assembling nanoparticle drug carrier systems composed of three layers: a ceramic core, an oligomer coat, and a loaded biochemically active molecule. Aquasomes are utilized for targeted drug delivery to achieve specific therapeutic effects, and are biocompatible, biodegradable, and stable. Due to their structure, aquasomes are capable of delivering several types of substrates, and can be used for applications such as delivery of antigens, insulin, and hemoglobin. Aquasomes were first investigated by Kossovsky et al. in 1996 in experiments proposing their use in antigen delivery, drug delivery, and hemoglobin delivery systems. This initial research described aquasomes as self-assembling, with a novel surface modification process allowing the immobilization of drugs on the surface. The research was intended to address the molecular denaturation of polypeptide pharmaceuticals. Kossovsky et al. suggested that this system would be able to combat physical and chemical degradative agents affecting bioactive molecules while preserving the molecular structure of the drug. Since this initial exploration, the understanding of the composition and applications of aquasomes has increased. After each individual layer is synthesized, aquasomes self-assemble into triple-layered particles. The tri-layer structure enables aquasomes to deliver and release poorly soluble drugs in a controlled manner. Delivery of these poorly soluble drugs within aquasomes increases their solubility, bioavailability, and stability.
While not meeting the previous definition of (transcriptional) attenuation, these are now considered to be variants of the same phenomena and are included in this article. Attenuation is an ancient regulatory system, prevalent in many bacterial species providing fast and sensitive regulation of gene operons and is commonly used to repress genes in the presence of their own product (or a downstream metabolite).
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.